佐々木　裕伸 (ササキ　ヒロノブ)

Sasaki, Hironobu

写真a

所属（所属キャンパス）

医学部 予防医療センター （信濃町）

職名

特任助教（有期）
このページの先頭へ▲

学歴 【 表示 ／ 非表示 】

  • 2007年04月
    -
    2013年03月

    慶應義塾大学

    大学, 卒業

  • 2017年04月
    -
    2021年03月

    慶應義塾大学

    大学院, 修了, 博士

このページの先頭へ▲

学位 【 表示 ／ 非表示 】

  • 学士, 慶應義塾大学, 2013年03月

  • 博士（医学）, 慶應義塾大学, 課程, 2021年03月

    Associations of birthweight and history of childhood obesity with beta cell mass in Japanese adults

このページの先頭へ▲

免許・資格 【 表示 ／ 非表示 】

  • 日本内科学会 認定内科医, 2016年09月

  • 日本医師会 認定健康スポーツ医, 2017年03月

  • 日本医師会 認定産業医, 2019年07月

  • 日本糖尿病学会 糖尿病専門医, 2019年11月

  • 日本糖尿病協会 糖尿病認定医, 2019年12月

全件表示 >>

このページの先頭へ▲
 

研究分野 【 表示 ／ 非表示 】

  • ライフサイエンス / 代謝、内分泌学 (ヒト膵島研究)

このページの先頭へ▲

研究キーワード 【 表示 ／ 非表示 】

  • 糖尿病

このページの先頭へ▲
 

論文 【 表示 ／ 非表示 】

  • Increased alpha cell to beta cell ratio in patients with pancreatic cancer

    Tami Tsuchiya, Yoshifumi Saisho, Jun Inaishi, Hironobu Sasaki, Midori Sato, Masaru Nishikawa, Yohei Masugi, Taketo Yamada, Hiroshi Itoh

    Endocrine journal （Japan Endocrine Society)  2022年08月

    研究論文（学術雑誌）, 共著, 査読有り,  ISSN  0918-8959

    　概要を見る

    The development of pancreatic cancer (PC) is associated with worsening of glucose tolerance. However, there is limited information about the effects of PC on islet morphology. The aim of this study was to elucidate changes in alpha and beta cell mass in patients with PC. We enrolled 30 autopsy cases with death due to PC (9 with diabetes; DM) and 31 age- and BMI-matched autopsy cases without PC (controls, 12 with DM). Tumor-free pancreatic sections were stained for insulin and glucagon, and fractional beta cell (BCA) and alpha cell area (ACA) were quantified. In addition, expression of de-differentiation markers, i.e., ALDH1A3 and UCN3, was qualitatively evaluated. The pancreas of subjects with PC showed atrophic and fibrotic changes. There was no significant difference in BCA in subjects with PC compared to controls (1.53 ± 1.26% vs. 0.95 ± 0.42%, p = 0.07). However, ACA and ACA to BCA ratio were significantly higher in subjects with PC compared to controls (2.48 ± 2.39% vs. 0.53 ± 0.26% and 1.94 ± 1.93 vs. 0.59 ± 0.26, respectively, both p < 0.001). Increased ACA to BCA ratio was observed in subjects with PC irrespective of the presence of DM. Qualitative evaluation of ALDH1A3 and UCN3 expression showed no significant difference between the groups. In conclusion, in subjects with PC, alpha to beta cell mass ratio is increased, which may contribute to the increased risk of worsening glucose metabolism. Further studies are warranted to elucidate the mechanisms of increased alpha to beta cell mass in patients with PC.

  • Could the development of COVID-19 vaccine-induced type 1 diabetes be explained by a simple mechanism?

    Hironobu Sasaki, Arata Itoh, Hiroshi Itoh

    Diabetes & Metabolism （Elsevier BV)  48 （ 4 ） 101338 2022年07月

    研究論文（学術雑誌）, 共著, 筆頭著者, 査読有り,  ISSN  1262-3636

  • Newly developed type 1 diabetes after coronavirus disease 2019 vaccination: A case report

    Hironobu Sasaki, Arata Itoh, Yasuhiro Watanabe, Yuya Nakajima, Yoshifumi Saisho, Junichiro Irie, Shu Meguro, Hiroshi Itoh

    Journal of Diabetes Investigation （John Wiley & Sons)  13 （ 6 ） 1105 - 1108 2022年06月

    研究論文（学術雑誌）, 共著, 筆頭著者, 査読有り,  ISSN  2040-1116

    　概要を見る

    The vaccine for the coronavirus disease 2019 (COVID-19) has been reported to potentially cause or worsen diabetes. A 73-year-old Japanese woman received two doses of Moderna COVID-19 vaccine. Four weeks after the second vaccination, her glycemic control began to deteriorate, and 8 weeks after the second vaccination, the patient was diagnosed with new-onset type 1 diabetes that was strongly positive for autoantibodies and showed a disease-susceptible human leukocyte antigen haplotype, DRB1*04:05:01-DQB1*04:01:01. The glucagon stimulation test suggested an insulin-dependent state, and induction of intensive insulin therapy brought about fair glycemic control. The time period from the COVID-19 vaccination to the development of type 1 diabetes was relatively longer than to the onset or exacerbation of type 2 diabetes, as previously reported, suggesting the complicated immunological mechanisms for the destruction of β-cells associated with the vaccination. In recipients with the disease-susceptible haplotypes, one should be cautious about autoimmune responses for several months after the vaccination.

  • Dipeptidyl peptidase-4 inhibitors and beta cell mass in Japanese adults with type 2 diabetes

    Hironobu Sasaki, Yoshifumi Saisho, Hiroshi Itoh

    Endocrine Practice （Elsevier BV)  28 （ 5 ） 563 - 564 2022年05月

    研究論文（学術雑誌）, 共著, 筆頭著者, 査読有り,  ISSN  1530-891X

  • Changes in glycemic variability, gastric emptying and vascular endothelial function after switching from twice-daily to once-weekly exenatide in patients with type 2 diabetes: a subpopulation analysis of the twin-exenatide study

    Jun Inaishi, Yoshifumi Saisho, Yuusuke Watanabe, Tami Tsuchiya, Hironobu Sasaki, Tatsuhiro Masaoka, Hiroshi Itoh

    BMC Endocrine Disorders （BioMed Central)  22 （ 1 ） 20 2022年01月

    研究論文（学術雑誌）, 共著, 査読有り

    　概要を見る

    Background: We investigated the changes in blood glucose fluctuation, gastric emptying, and vascular endothelial function by switching from an exenatide twice-daily formulation (BID) to a once-weekly formulation (QW) since the evaluation of postprandial glucose excursion and glycemic variability (GV) by continuous glucose monitoring (CGM) after switching was lacking. Methods: Twenty-nine patients with type 2 diabetes treated with exenatide BID were included in this study and switched to exenatide QW for 24 weeks. GV assessed by CGM, gastric emptying (by 13 C-acetate breath test) and vascular endothelial function (by reactive hyperemia - peripheral arterial tonometry) were evaluated at baseline and 24 weeks after switching. Results: HbA1c decreased significantly from the baseline to week 24, while postprandial glucose levels after breakfast and dinner significantly increased (both P <0.05). However, the increases in GV indices were modest and not statistically significant at week 24. Vascular endothelial function was also not significantly changed after switching (P >0.05). Gastric emptying was significantly accelerated at week 24 (Tmax 83.4 ± 12.1 min vs. 58.2 ± 16.4 min) (P <0.001) and correlated with increased postprandial glucose levels after breakfast and dinner (both P <0.05). Conclusions: Despite the increase in postprandial glucose associated with accelerated gastric emptying after switching from exenatide BID to QW, change in GV was modest and no significant deterioration in vascular endothelial function was observed after switching. These results support the superiority of treatment with exenatide QW over exenatide BID in clinical practice; however, attention should be paid to the monitoring and management of postprandial glucose levels when selecting exenatide QW. Trial registration: Clinical trial registry number; UMIN000016390 and jRCTs031180320. Approval date of Registry and the Registration: December 12, 2014.

全件表示 >>

このページの先頭へ▲

受賞 【 表示 ／ 非表示 】

  • 日本抗加齢医学会 若手研究者賞

    2022年12月, 日本抗加齢医学会

    受賞区分： 国内学会・会議・シンポジウム等の賞

  • 東京都医師会 医学研究賞奨励賞

    2021年12月, 東京都医師会

    受賞区分： 出版社・新聞社・財団等の賞

  • 日本糖尿病学会年次学術集会 Young Investigator Award

    2021年05月, 日本糖尿病学会

    受賞区分： 国内学会・会議・シンポジウム等の賞

  • 日本ホルモンステーション Clinical Investigator Award

    2020年10月, 日本ホルモンステーション

    受賞区分： 出版社・新聞社・財団等の賞

このページの先頭へ▲
 

委員歴 【 表示 ／ 非表示 】

  • 2020年
    -
    継続中

    日本内科学会　専門医制度審議会　病歴要約査読委員

このページの先頭へ▲